MX356808B - Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia. - Google Patents

Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.

Info

Publication number
MX356808B
MX356808B MX2014003402A MX2014003402A MX356808B MX 356808 B MX356808 B MX 356808B MX 2014003402 A MX2014003402 A MX 2014003402A MX 2014003402 A MX2014003402 A MX 2014003402A MX 356808 B MX356808 B MX 356808B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
caquexy
antibody
treatment
subject
Prior art date
Application number
MX2014003402A
Other languages
English (en)
Other versions
MX2014003402A (es
Inventor
Simard John
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of MX2014003402A publication Critical patent/MX2014003402A/es
Publication of MX356808B publication Critical patent/MX356808B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a el uso de una composición farmacéutica que comprende un portador farmacéutico aceptable y una cantidad eficaz de Ab anti-IL-1a, para la manufactura de un medicamento para reducir la pérdida de masa corporal magra en un sujeto humano que tiene cáncer, el medicamento está adaptado para ser administrable a un sujeto y es efectivo para reducir la pérdida de masa corporal magra en el sujeto.
MX2014003402A 2011-09-23 2012-09-21 Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia. MX356808B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161538309P 2011-09-23 2011-09-23
PCT/US2012/056492 WO2013043973A2 (en) 2011-09-23 2012-09-21 Cachexia treatment

Publications (2)

Publication Number Publication Date
MX2014003402A MX2014003402A (es) 2015-03-05
MX356808B true MX356808B (es) 2018-06-14

Family

ID=47911521

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003402A MX356808B (es) 2011-09-23 2012-09-21 Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.

Country Status (16)

Country Link
US (2) US9809649B2 (es)
EP (1) EP2750709B1 (es)
JP (1) JP6204915B2 (es)
KR (1) KR102039198B1 (es)
CN (2) CN108404127B (es)
AU (1) AU2012312225B2 (es)
CA (1) CA2849710C (es)
DK (1) DK2750709T3 (es)
ES (1) ES2695102T3 (es)
IL (1) IL231622B (es)
MX (1) MX356808B (es)
PH (1) PH12014500645A1 (es)
PT (1) PT2750709T (es)
RU (1) RU2622021C2 (es)
WO (1) WO2013043973A2 (es)
ZA (1) ZA201402057B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
RU2013110030A (ru) 2010-08-23 2014-09-27 ИксБиотеч, Инк. Лечение неопластических заболеваний
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JPH08502300A (ja) 1992-10-14 1996-03-12 スターリング ウィンスロップ アイエヌシー． 治療および診断像形成組成物および方法
DE69427928T3 (de) 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
WO1997002479A2 (en) 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
US20040086507A1 (en) 2000-10-19 2004-05-06 Kenya Shitara Antibody inhibiting vplf activity
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
ME00204B (me) 2002-09-06 2011-02-10 Medarex Llc Terapijsko, humano, monoklonsko anti-il-1r1antitijelo
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
WO2006001967A2 (en) 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Migrastatin analogs in the treatment of cancer
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
US7718674B2 (en) 2004-09-27 2010-05-18 Bridge Pharma, Inc. Methods of relieving neuropathic pain with the S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine
CA2591148A1 (en) 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
CN101253409A (zh) 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
AU2006298767B2 (en) 2005-09-28 2013-01-10 Cytos Biotechnology Ag Interleukin-1 conjugates and uses thereof
BRPI0709977A2 (pt) 2006-04-14 2011-08-02 Novartis Ag uso de anticorpos de il-1 para o tratamento de distúrbios oftálmicos
JP2009537507A (ja) 2006-05-15 2009-10-29 エクスバイオテク インコーポレーティッド アテローム性動脈硬化症に対して保護的な自己抗体を誘導するＩＬ−１α免疫法
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
ES2374845T3 (es) 2006-05-22 2012-02-22 Xbiotech, Inc Tratamiento de cáncer con anticuerpos anti-il-1.
CL2007001536A1 (es) 2006-05-30 2008-01-25 Genentech Inc Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
WO2008082651A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
EP3632444A3 (en) 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
NZ590033A (en) * 2008-05-30 2011-08-26 Xbiotech Inc Interleukin-1alpha antibodies and methods of use
CA2737056C (en) 2008-09-12 2018-10-30 Xbiotech Inc. Targeting pathogenic monocytes
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
CN102655880A (zh) 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
PT2582391T (pt) 2010-06-18 2019-01-11 Xbiotech Inc Tratamento da artrite
RU2013110030A (ru) 2010-08-23 2014-09-27 ИксБиотеч, Инк. Лечение неопластических заболеваний
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
CN103442733A (zh) 2011-04-01 2013-12-11 埃克斯生物科技公司 皮肤病学病状的治疗
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
EP4628162A3 (en) 2012-10-04 2025-12-03 XBiotech Inc. Treating vascular disease and complications thereof
EP2903643A4 (en) 2012-10-04 2016-06-15 Xbiotech Inc TREATMENT OF PSYCHIATRIC DISEASES

Also Published As

Publication number Publication date
US20130078258A1 (en) 2013-03-28
PH12014500645A1 (en) 2014-05-05
US10202449B2 (en) 2019-02-12
DK2750709T3 (en) 2018-12-03
CA2849710A1 (en) 2013-03-28
KR102039198B1 (ko) 2019-10-31
MX2014003402A (es) 2015-03-05
ES2695102T3 (es) 2019-01-02
KR20140078690A (ko) 2014-06-25
RU2622021C2 (ru) 2017-06-08
JP6204915B2 (ja) 2017-09-27
AU2012312225B2 (en) 2017-10-05
AU2012312225A1 (en) 2014-04-10
CN108404127A (zh) 2018-08-17
CN108404127B (zh) 2025-12-12
CN103906536A (zh) 2014-07-02
ZA201402057B (en) 2016-08-31
HK1199616A1 (en) 2015-07-10
CA2849710C (en) 2020-04-28
JP2014526559A (ja) 2014-10-06
WO2013043973A2 (en) 2013-03-28
EP2750709B1 (en) 2018-08-15
US20180037647A1 (en) 2018-02-08
RU2014111662A (ru) 2015-10-27
IL231622A0 (en) 2014-05-28
IL231622B (en) 2018-10-31
PT2750709T (pt) 2018-11-22
US9809649B2 (en) 2017-11-07
EP2750709A4 (en) 2015-06-10
EP2750709A2 (en) 2014-07-09

Similar Documents

Publication Publication Date Title
MX356808B (es) Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX380273B (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
CL2016002132A1 (es) Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
CO6311008A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+
PE20142363A1 (es) Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab
MX350781B (es) Anticuerpo anti-humano trop-2 que tiene actividad anti-tumoral in vivo.
CO6751277A2 (es) Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes
MX348581B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
MY175764A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
EA201592040A1 (ru) Иммуногенная композиция для применения в терапии
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.

Legal Events

Date Code Title Description
FG Grant or registration